News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celator Pharmaceuticals, Inc. Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia


1/26/2012 7:20:16 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced that the European Commission (EC) has granted orphan drug status to CPX-351, the company’s proprietary “liposomal combination of cytarabine and daunorubicin,” for the treatment of acute myeloid leukemia (AML). The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES